ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
SEOUL, South Korea — ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis.
Article content
Article content
The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG.
Article content
'This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders', said Dr. Dongjo Kim, the CEO of ImmunAbs, 'we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.'
Article content
About Myasthenia Gravis
Article content
Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications. While existing C5 inhibitors have contributed to improved remission rates, many patients still experience residual disease activity due to incomplete complement inhibition. In addition to autoantibody-mediated activation of the classical complement pathway, MG pathogenesis is also significantly influenced by activation of the alternative pathway. ImmunAbs believes that comprehensive inhibition of both the classical and alternative pathways is essential for minimizing residual complement activity and enabling revolutionary treatments for MG.
Article content
About IM-101
Article content
IM-101 is a humanized monoclonal antibody targeting complement C5 with high affinity. In the recently concluded Phase 1 clinical trial, IM-101 demonstrated an excellent safety profile and was well tolerated at all tested doses, with no dose-limiting toxicity or severe adverse events observed. The clinical results showcasing IM-101's outstanding ability to reduce serum free C5 concentrations in healthy volunteers provide strong evidence of its superior efficacy in complement inhibition.
Article content
ImmunAbs is a clinical-stage biotechnology company established in 2017. Committed to delivering transformative treatments globally, the company aims to develop novel antibody therapeutics, particularly concentrating its efforts on the lead program targeting severe autoimmune diseases. Supported by equity funding and national grants from KDDF, which covered development from non-clinical through Phase 1 clinical studies, ImmunAbs is now seeking global partnerships to accelerate the advancement of IM-101 towards market availability.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 hours ago
- Globe and Mail
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.99. In the year-ago period, the company had reported a loss of $3.33. Total revenues in the quarter were $142 million, which beat the Zacks Consensus Estimate of $127 million. Revenues declined by around 41% year over year, owing to lower net product sales. More on MRNA's Q2 Earnings Moderna currently has two marketed vaccines in its portfolio, the COVID-19 vaccine Spikevax and the recently launched RSV vaccine mResvia. Product sales were down 38% year over year to $114 million due to lower Spikevax sales. Per Moderna, almost the entirety of this number was generated from Spikevax, with a 'negligible' contribution from mResvia. Moderna generated $28 million from grants, collaborations, licensing and royalty revenues in the quarter, down 51% year over year. The company usually earns collaboration revenues from agreements with several big pharma/biotech companies, including Merck MRK and Vertex Pharmaceuticals. Operating Costs Decline Amid Streamlining Efforts Selling, general and administrative (SG&A) expenses were $230 million, down 14% year over year. This downside was primarily due to broad-based cost-cutting activities. Research & development (R&D) expenses were down 43% to $700 million, driven by the reduction in clinical spending across respiratory programs due to the timing of clinical studies and program wind-downs. MRNA Revises '25 Outlook Moderna revised its total revenue guidance for the full year, which was initially issued in January. It now expects total revenues in the range of $1.5-$2.2 billion, which reflects a $300 million cut from the upper end of the previous guidance of $1.5-$2.5 billion. Per the company, this revision is mainly driven by the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026. Shares of Moderna were down 6% in pre-market trading today, attributed to the downgrade in guidance. Year to date, the stock has underperformed the industry. Owing to the seasonality of its respiratory business, Moderna is expected to generate the majority of the guided revenue in the second half of the year. The company has already recorded total revenues worth $250 million in the first half of 2025. For the second half, Moderna expects a revenue split of 40-50% in the third quarter, with the balance in the fourth quarter. MRNA also lowered the guidance for R&D expenses during the quarter, now expecting to incur between $3.6 billion and $3.8 billion (previous guidance: $4.1 billion). This is likely to be due to the company's plans to cut nearly 10% workforce, as announced yesterday. Moderna reiterated its projections for SG&A expenses to be around $1.1 billion. The company also lowered its forecasts for capital expenditure to be about $0.3 billion (previous guidance: $0.4 billion). Moderna expects to end 2025 with cash, cash equivalents and investments of nearly $6 billion. MRNA's Recent Pipeline Updates The company secured three regulatory approvals from the FDA in the past few months. These include label expansion for using mResvia in high-risk adults aged 18-59 and full approval for Spikevax in pediatric patients aged between six months through 11 years old (previously granted emergency use authorization for this population by the agency). The FDA also approved mNexspike, a next-generation refrigerator-stable version of Spikevax. Moderna is also evaluating several pipeline candidates in late-stage development. Last month, the company reported that a phase III efficacy study (P304) showed that its influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy to an approved flu shot marketed by GSK. The above results not only supports potential approval of the standalone flu shot but also strengthen the case for refiling mRNA-1083, an investigational combination vaccine against COVID-19 and influenza. In May, Moderna voluntarily withdrew a filing with the FDA for mRNA-1083 after the agency requested additional efficacy data for the flu component. This candidate integrates the company's COVID-19 shot with mRNA-1010. Moderna is currently in discussions with the FDA regarding data requirements for resubmitting the regulatory filing. An important candidate in the company's pipeline is intismeran autogene, a personalized cancer therapy, which is being developed in collaboration with Merck. The companies are evaluating the therapy in three pivotal phase III studies, one in the melanoma indication and the other two in the non-small cell lung cancer space. It is also being evaluated in separate mid-stage studies for high-risk bladder cancers (both muscle-invasive and non-muscle-invasive) and adjuvant renal cell carcinoma. Moderna and Merck recently launched a new phase II study evaluating the therapy as a first-line treatment for patients with metastatic melanoma. In a separate press release, Moderna announced that the U.K. Court of Appeal has upheld the validity of its EP'949 patent and infringement by Pfizer PFE / BioNTech 's BNTX COVID-19 vaccine Comirnaty. The patent relates to chemically modified mRNA, one of the company's foundational technologies that enables the development of mRNA-based medicines. The latest decision affirms the High Court's initial ruling from last year, which was also in Moderna's favor. MRNA's Zacks Rank Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Globe and Mail
15 hours ago
- Globe and Mail
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Regeneron Pharmaceuticals, Inc. ( REGN ) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which comfortably beat the Zacks Consensus Estimate of $8.03. The bottom line increased 12% from $11.56 recorded in the year-ago quarter. The improvement can be attributed to higher revenues. Total revenues grew 4% year over year to $3.7 billion due to higher sales of Eylea HD and increased Dupixent profits. Revenues also beat the Zacks Consensus Estimate of $3.3 billion. Sales of the oncology drug Libtayo also beat estimates. Shares are trading up in response to the better-than-expected quarterly results. Regeneron's shares have lost 23.4% year to date compared with the industry 's decline of 0.3%. Eylea HD, Dupiexent Power REGN's Q2 Results Eylea's sales in the United States plunged 39% year over year to $754 million, primarily due to increased competition from other drugs like Roche's (RHHBY) Vabysmo, loss in market share to compounded bevacizumab due to patient affordability constraints and transition of patients to higher doses of the drug (Eylea HD). Nonetheless, Eylea sales in the United States beat the Zacks Consensus Estimate of $686 million. Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG ( BAYRY ). Regeneron records net product sales of Eylea in the United States and Bayer does the same outside the country. The company records its share of profits in connection with Eylea sales outside the United States as collaboration revenues. In August 2023, the FDA approved Eylea HD (higher dose of Eylea) for the treatment of patients with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. Eylea HD generated revenues of $393 million in the United States, up 29% year over year, due to higher sales volumes driven by increased demand. Eylea HD sales beat the Zacks Consensus Estimate of $320 million. Total revenues include collaboration revenues of $1.9 billion from Sanofi ( SNY ) and Bayer. The figure increased 22.1% from that recorded in the year-ago quarter. Total collaboration revenues beat the Zacks Consensus Estimate of $1.7 billion. Sanofi's collaboration revenues increased 26% to $1.44 billion, driven by profits associated with higher Dupixent sales. The figure beat the Zacks Consensus Estimate of $1.36 billion. We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs. Dupixent's sales increased 22% year over year to $4.3 billion. Bayer's collaboration revenues totaled $415 million, up 11% year over year. Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales. Total Libtayo sales were $376.5 million, up 27% year over year. The figure beat the Zacks Consensus Estimate of $322 million. Praluent's net sales in the United States were $65.8 million. Kevzara recorded global sales of $152.2 million, up 39% from the year-ago quarter's level. Gross margin on net product sales decreased to 86% from 89% due to ongoing investments to support the manufacturing operations and higher inventory write-offs and reserves in the second quarter of 2025 compared to the second quarter of 2024. Adjusted R&D expenses increased 20% year over year to $1.3 billion due to the advancement of the company's pipeline. Adjusted SG&A expenses decreased 19% to $542 million. In February 2025, the board of directors authorized a new share repurchase program to repurchase up to an additional $3.0 billion of the common stock. During the second quarter of 2025, REGN repurchased shares for $1.07 billion. As of June 30, 2025, approximately $2.814 billion remained available for share repurchases. Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote REGN's Key Pipeline and Regulatory Updates The FDA approved a label expansion of Dupixent for the treatment of adults with bullous pemphigoid. Regulatory applications are under review in the European Union (EU) and Japan. In April, the FDA approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment. Regeneron expects regulatory approvals to be delayed for its currently pending FDA applications for Eylea HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have target action dates in August 2025. The anticipated delay is related to observations from an FDA general site inspection at the filler for Eylea HD in these regulatory applications, Catalent Indiana LLC (which was recently acquired by Novo Nordisk). In July 2025, the FDA granted accelerated approval to Lynozyfic (linvoseltamab) to treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. The drug is also approved in the EU for the same indication. The FDA accepted for priority review a supplemental biologics license application (sBLA) for Libtayo (cemiplimab) in adjuvant CSCC, with a target action date in October 2025. However, the FDA recently issued a complete response letter for the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. The BLA was impacted by the Catalent Indiana LLC site inspection. REGN recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau. Our Take on REGN's Q2 Performance Regeneron's performance in the second quarter was encouraging. The company has finally managed to post revenue growth despite declining sales of lead drug Eylea. Eylea sales continue to be on the downslide due to competition from Vabysmo. We note that Vabysmo's uptake has been outstanding. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. REGN is looking to strengthen its oncology portfolio to diversify its revenue stream. The recent progress with its oncology pipeline has been encouraging. The approval of Lynozyfic is a boost for its oncology portfolio. Zacks Rank Regeneron currently carries a Zacks Rank #4 (Sell). You can see . Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Toronto Star
16 hours ago
- Toronto Star
Protein Industries Canada and Nurasa Launch Program to Expand Global Reach of Canadian Plant-Based Companies into the Asia-Pacific Market
Singapore, Aug. 01, 2025 (GLOBE NEWSWIRE) — Today at an event in Singapore, witnessed by Minister MacDonald, Minister of Agriculture and Agri-Food Canada, Protein Industries Canada announced a new international partnership with Nurasa, a leading food innovation and commercialization partner based in Singapore. The partnership will help Canadian companies accelerate entry into the fast-growing Asia-Pacific market—one of the world's largest and most dynamic regions for plant-based food innovation. 'Canadian innovation is driving the global shift toward sustainable food solutions.' Said the Honourable Melanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. 'By supporting our plant-based companies as they expand into new markets like the Asia-Pacific, we are helping them scale up, create good jobs at home, and showcase Canadian expertise on the world stage. This partnership is another example of how the Global Innovation Clusters are helping Canadian businesses succeed both at home at abroad, driving Canada's leadership in industries of the future.'
